Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Previously Treated Non-Squamous NSCLC
NCT04310007Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2020
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cabozantinib and nivolumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (4 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival. Started Jul 2020; status: active, not recruiting.
02
Drugs
cabozantinibnivolumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04310007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04310007.